From “Digitize a Logbook” to End-to-End Execution: A Playbook for Scoping Digital Transformation in Pharma

Digital transformation in pharma often begins with something small: replace a logbook, reduce manual entry, improve data visibility. But when the technology is highly flexible, success creates its own challenge. What starts as a contained project can quickly expand into something much larger.

At Operations Calling, Jason Gillespie from Jazz Pharmaceuticals shared how a logbook digitization effort evolved into an end-to-end production execution program. As teams saw what was possible, scope expanded with more apps, more processes, more ambition.

In this blog, we’ll break down the playbook they used to control that expansion: how they scoped the work, separated platform validation from process governance, aligned QA early, and turned flexibility into structured, scalable transformation instead of uncontrolled scope creep.

Flexible platforms make it easy to build, and once teams see what’s possible, momentum builds quickly.

At Jazz, the initial goal was simple: digitize logbooks. But once teams experienced the system in action, the appetite grew. More use cases emerged. More processes were brought into scope.

“We started off thinking we were only going to deploy 10 apps… that number doubled. Along the way, 183 improvement ideas surfaced.” — Jason Gillespie, Digital Enterprise Capabilities Business Partner, Jazz Pharmaceuticals.

This wasn’t a sign of failure. It was a sign the approach was working.

The challenge wasn’t limiting expansion. It was structuring it.

In GxP manufacturing, every new workflow brings validation and governance considerations. Jazz’s focus was on how to scale that demand intentionally, maximizing the value of the platform while maintaining control over validation, ownership, and release.

Flexibility didn’t create risk. It created opportunity. The work was in ensuring that opportunity translated into structured, controlled expansion.

Flexible platforms make it easy to build. They also make it easy to expand. Once teams see what’s possible, scope grows with more apps, more processes, more ambition.

Step 1: Scope the Problem Before You Scope the Technology

It is easy to get lost in the details of the technology and what is possible. When teams take a step back and understand the most pressing challenges, it becomes easier to plan solutions that are high impact for the scope of work.

Before approving a project roadmap, define what the initiative is meant to improve and make those criteria explicit.

Expansion should be evaluated against operational impact:

• Eliminate manual processes and save hours

• Improve quality review times

• Reduce deviations

• Enable usable digital data

Those priorities become the filter. New use cases must be challenge-tested: What is this doing for us? How is it transforming the process? What benefits is it bringing? If the answer isn’t clear, it shouldn’t move forward.

In regulated environments, every added workflow increases validation and governance responsibility. Growth must be justified, not assumed. Scope the objective first. Then allow the system footprint to expand in response to proven value.

Step 2: Structure the Work Into Platform, Process, and Governance

As digital transformation in pharma manufacturing expands, complexity doesn’t come from the apps. It comes from blurred ownership.

Who owns lifecycle control?
Who validates what?
Who approves the release?
Who is accountable during an inspection?

If those answers aren’t clear early, expansion slows or worse, confidence erodes.

A scalable model separates the work into three defined containers.

Platform
Own the architecture once. Define how applications are structured, versioned, migrated, and controlled across environments. Build for scale from day one.
Benefit: You avoid re-validating architecture every time a new workflow is added.

Process
Challenge-test and redesign the workflow before digitizing it. Don’t replicate paper inefficiencies in software. Use digitization as an opportunity to simplify steps, remove redundant checks, and standardize how work is performed.
Benefit: Reduces rework and prevents hidden edge cases from surfacing during validation.

Governance
Separate platform governance from process validation. Digital QA validates the platform and defines lifecycle controls. Site QA validates the application in the context of the process and controls the final release.
Benefit: QA maintains authority, inspection readiness stays intact, and ownership remains clear as scope expands.

These streams can run in parallel. They just shouldn’t collapse into one. The outcome isn’t theoretical. It’s practical:

• Faster app deployment

• Lower validation friction

• Clear inspection narrative

• Controlled expansion

Structure is what allows flexibility to scale without creating disruption.

Step 3: Treat Digitization as Process Redesign

Digitization should not begin with configuration. It should begin with questioning.

One of the most common mistakes in digital transformation in pharma manufacturing is translating existing SOPs directly into software. It feels efficient. It preserves familiarity. But it also preserves inefficiency, redundancy, and undocumented workarounds.

Before building applications, the process itself needs to be examined:

• Which steps exist because of paper constraints?

• Where are second checks compensating for poor visibility?

• What reconciliations are manual simply because data isn’t connected?

• Where does tribal knowledge override what’s written in the SOP?

This discovery phase is challenge-testing.

Teams that skip this step often discover edge cases during validation or go-live. That leads to rework, additional test cycles, and scope adjustments mid-stream.

Teams that invest time here reduce downstream friction.

“It’s more of a people change, a culture change, a process change… the technology is last mile stuff.”— Jason Gillespie, Digital Enterprise Capabilities Business Partner, Jazz Pharmaceuticals

Digitization is a forcing function. It exposes ambiguity. It surfaces inconsistencies. It reveals where processes were never fully standardized. Treat that moment as redesign and not replication.

Because once inefficiency is coded into an application, it becomes much harder to remove.

Step 4: Earn QA Trust Early Through Structured Validation

In GxP manufacturing, digital transformation doesn’t scale unless QA is confident in the system.

Flexible platforms can raise immediate questions:
How should this be validated?
What is the risk classification?
Is this infrastructure, application, or both?

One effective strategy is to validate conservatively in the early phase.

That may mean combining unit testing and end-to-end process testing. It may mean recording executed sessions for review. It may mean documenting far more test steps than will ultimately be required long term.

The objective isn’t to maximize paperwork. It’s to remove ambiguity.

A structured approach often includes separating responsibilities:

• Platform-level governance and lifecycle controls are owned centrally

• Application-level validation is owned by site QA

• Clear release authority resting with quality

This separation prevents confusion over accountability and keeps inspection narratives clean.

Over time, once platform behavior is understood and lifecycle controls are proven, validation effort can shift toward a more risk-based model.

But efficiency should follow trust. In regulated environments, acceleration comes from confidence. And confidence is built through structured, visible validation discipline.

Step 5: Control Scope With Sprints and Metric Gates

Momentum doesn’t come from flexibility alone. Momentum comes from seeing what’s possible, when teams realize how quickly they can digitize a process, simplify a workflow, or eliminate manual steps. Once that momentum builds, it needs boundaries.

As expansion accelerates, two risks emerge: adding too much at once, and solving edge cases mid-build.

The concern is control. The mechanism that prevents drift restricts ideas.

First, work should be structured into short, defined cycles like two-week sprints with predetermined outcomes. Sessions should be time-boxed. Feedback loops should be built in. Development moves forward in increments rather than large releases.

Second, expansion should be metric-gated. New use cases have to pass the same operational criteria defined at the start. If you don’t materially improve effort, oversight, or deviation risk, you wait.

Sprints control pace and metric gates control priority. Together, you can prevent flexibility from turning into sprawl.

In GxP manufacturing, scope discipline is about sequencing correctly, so transformation expands deliberately, not reactively.

When scope is controlled and validation builds confidence, expansion becomes sustainable.

What begins as a single workflow can extend across scheduling, line clearance, execution steps, cleaning, and packaging by connecting processes that were previously isolated.

Verification steps embedded directly into workflows ensure operators complete and document each step correctly, reducing reliance on manual second-person checks and simplifying batch review.

Visibility follows execution. Once workflows are digitized, performance insight emerges naturally.

End-to-end execution doesn’t require a monolithic deployment.

It can evolve in structured, validated increments.

Tulip supports this structured approach by separating platform governance from process execution.

Teams first establish architecture, lifecycle controls, and validation strategy at the platform level. From there, they incrementally build process-specific applications within defined boundaries.

With Tulip’s platform, pharma teams can expand in logical increments like logbooks, scheduling, cleaning, and execution steps, all without committing to a monolithic deployment. Teams can evolve apps through controlled versioning, with QA maintaining release authority and visibility into changes.

Guardrails can be embedded directly into workflows, reducing reliance on manual second checks while preserving compliance controls.

This enables digital transformation in pharma manufacturing to scale deliberately: start with a contained use case, validate rigorously, apply clear governance, and expand across production with increasing confidence, not increasing risk.